Glycopyrrolate Oral Solution, 1 mg/5 mL recall — Precision Dose Inc. (Class II)
Precision Dose Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Glycopyrrolate Oral Solution, 1 mg/5 mL — a Class II recall, initiated 2026-07-14 and posted to the FDA enforcement report on 2026-07-29, under recall number D-0741-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications”. From the product description, the form is oral solution, the strengths given are 1 mg/5 mL and 5 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 68094-073-01. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in IL, United States. It is the only recall number the FDA has filed under event ID 99388. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0741-2026 |
|---|---|
| FDA event ID | 99388 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Precision Dose Inc. |
| Recall initiated | 2026-07-14 |
| Reported by FDA | 2026-07-29 |
| Report lag | 15 days from initiation to report |
| Distribution | US Nationwide. — Nationwide (US) |
| Firm location on record | IL, United States |
| Product description (source) | Glycopyrrolate Oral Solution, 1 mg/5 mL, delivers 5 mL, Rx only, Pkg: Precision Dose, Inc, S. Beloil, IL 61080, unit-dose oral syringes, NDCs 68094-073-01 (oral syringe) and 68094-073-58 (case). |
Reason reported by FDA
Failed Impurities/Degradation Specifications
3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
5 identifying values matched by exact pattern in the 29-word product description above; each is a literal substring of it.
| Product named | Glycopyrrolate Oral Solution |
|---|---|
| Form | Oral Solution |
| Strength | 1 mg/5 mL · 5 mL |
| NDC | s: 68094-073-01 |
| Marketing category | Rx only |
Other indexed recalls of glycopyrrolate
2 indexed records name glycopyrrolate as the recalled substance. Matching is on the product-name prefix of the FDA's own text, so other strengths and packages are included.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Glycopyrrolate Injection, 1 mg | D-0725-2026 | Fresenius Kabi Usa, LLC | 1 mg · Injection | 2026-07-29 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Levothyroxine Sodium Tablets, 25 mcg | D-0700-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0701-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0702-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 88 mcg | D-0703-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 112 mcg | D-0704-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 125 mcg | D-0705-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 150 mcg | D-0706-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 25 mcg | D-0707-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-07-29 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Levothyroxine Sodium Tablets, 50 mcg | D-0708-2026 | Major Pharmaceuticals | 50 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0709-2026 | Major Pharmaceuticals | 75 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 125 mcg | D-0710-2026 | Major Pharmaceuticals | 125 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 150 mcg | D-0711-2026 | Major Pharmaceuticals | 150 mcg · Tablets | 2026-07-29 |
| Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg | D-0712-2026 | Ascend Laboratories, LLC | 10 mg/20 mg · Tablets | 2026-07-29 |
| Rohto Cooling Eye Drops ALL-IN-ONE, 0.2% | D-0715-2026 | Rohto-mentholatum (vietnam) Co., Ltd. | 0.2% · Eye Drops | 2026-07-29 |
| Rohto Cooling Eye Drops Max Strength, 0.03% | D-0716-2026 | Rohto-mentholatum (vietnam) Co., Ltd. | 0.03% · Eye Drops | 2026-07-29 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 68094-073-01 (s) at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Precision Dose Inc. (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0741-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0741-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-29
- Ingested
- 2026-08-22
- Record hash
64fce23a4c598dbb
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.